CA3084034C - Covalent anesthetic-polymer conjugates for prolonged local anesthesia - Google Patents
Covalent anesthetic-polymer conjugates for prolonged local anesthesia Download PDFInfo
- Publication number
- CA3084034C CA3084034C CA3084034A CA3084034A CA3084034C CA 3084034 C CA3084034 C CA 3084034C CA 3084034 A CA3084034 A CA 3084034A CA 3084034 A CA3084034 A CA 3084034A CA 3084034 C CA3084034 C CA 3084034C
- Authority
- CA
- Canada
- Prior art keywords
- ttx
- anesthetic
- peg
- pgs
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593784P | 2017-12-01 | 2017-12-01 | |
| US62/593,784 | 2017-12-01 | ||
| PCT/US2018/063573 WO2019109065A1 (en) | 2017-12-01 | 2018-12-03 | Covalent anesthetic-polymer conjugates for prolonged local anesthesia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3084034A1 CA3084034A1 (en) | 2019-06-06 |
| CA3084034C true CA3084034C (en) | 2022-08-16 |
Family
ID=64734233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3084034A Active CA3084034C (en) | 2017-12-01 | 2018-12-03 | Covalent anesthetic-polymer conjugates for prolonged local anesthesia |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210275678A1 (enExample) |
| EP (1) | EP3717017A1 (enExample) |
| JP (2) | JP7601375B2 (enExample) |
| CN (1) | CN111867633B (enExample) |
| AU (1) | AU2018375002B2 (enExample) |
| CA (1) | CA3084034C (enExample) |
| WO (1) | WO2019109065A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4090374A4 (en) * | 2020-01-17 | 2024-10-09 | Children's Medical Center Corporation | MACROMOLECULAR PRODRUGS FOR LIGHT EMITTING DIODES AND THEIR USES |
| CN113805326A (zh) * | 2021-09-18 | 2021-12-17 | 吉林大学 | 原位拉伸多光子激光共聚焦成像仪、实时原位三维观测共混聚合物内部结构的方法 |
| US20250099421A1 (en) * | 2023-09-27 | 2025-03-27 | Relevium Medical | Analgesic Therapeutics Based on conjugation of Biocompatible Polymers to Ion Channel Modulators |
| CN119345382B (zh) * | 2024-12-23 | 2025-03-21 | 上海华之沃生物医药科技有限公司 | 替曲朵辛偶联物、制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001413A (en) | 1973-06-12 | 1977-01-04 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition employing saxitoxin |
| US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| US6326020B1 (en) * | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
| GB0218830D0 (en) * | 2002-08-13 | 2002-09-18 | Syngenix Ltd | Anaesthetic conjugate |
| US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| US8980317B2 (en) * | 2008-12-23 | 2015-03-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating infections comprising a local anesthetic |
| EA201171195A8 (ru) * | 2009-03-30 | 2014-08-29 | Серулин Фарма Инк. | Конъюгаты, частицы, композиции "полимер-агент" и способы их применения |
| KR20140057414A (ko) | 2011-06-22 | 2014-05-12 | 바이옴 바이오사이언스 피브이티. 엘티디. | 컨쥬게이트계 항진균 및 항세균 프로드러그 |
| US9408846B2 (en) * | 2012-04-23 | 2016-08-09 | The Children's Medical Center Corporation | Formulations and methods for delaying onset of chronic neuropathic pain |
| ES2727292T3 (es) * | 2013-03-15 | 2019-10-15 | Childrens Medical Ct Corp | Formulaciones combinadas de neosaxitonina para una anestesia local prolongada |
| US10449152B2 (en) * | 2014-09-26 | 2019-10-22 | Covidien Lp | Drug loaded microspheres for post-operative chronic pain |
| CN106310289B (zh) * | 2015-06-24 | 2020-10-13 | 天津键凯科技有限公司 | 一种聚乙二醇和麻醉药的结合物及其制备方法 |
-
2018
- 2018-12-03 EP EP18821915.8A patent/EP3717017A1/en active Pending
- 2018-12-03 US US16/768,818 patent/US20210275678A1/en not_active Abandoned
- 2018-12-03 CA CA3084034A patent/CA3084034C/en active Active
- 2018-12-03 CN CN201880085421.5A patent/CN111867633B/zh active Active
- 2018-12-03 AU AU2018375002A patent/AU2018375002B2/en active Active
- 2018-12-03 WO PCT/US2018/063573 patent/WO2019109065A1/en not_active Ceased
- 2018-12-03 JP JP2020529484A patent/JP7601375B2/ja active Active
-
2024
- 2024-07-01 JP JP2024106268A patent/JP2024114970A/ja active Pending
- 2024-08-27 US US18/817,160 patent/US20250195671A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3084034A1 (en) | 2019-06-06 |
| WO2019109065A1 (en) | 2019-06-06 |
| JP2024114970A (ja) | 2024-08-23 |
| CN111867633A (zh) | 2020-10-30 |
| US20210275678A1 (en) | 2021-09-09 |
| AU2018375002B2 (en) | 2021-11-11 |
| AU2018375002A1 (en) | 2020-07-02 |
| EP3717017A1 (en) | 2020-10-07 |
| JP2021505550A (ja) | 2021-02-18 |
| JP7601375B2 (ja) | 2024-12-17 |
| CN111867633B (zh) | 2023-09-22 |
| US20250195671A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250195671A1 (en) | Covalent anesthetic-polymer conjugates for prolonged local anesthesia | |
| Zhang et al. | Long-acting hydrogel/microsphere composite sequentially releases dexmedetomidine and bupivacaine for prolonged synergistic analgesia | |
| CA2843503C (en) | Polymeric hyperbranched carrier-linked prodrugs | |
| RU2554854C9 (ru) | Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля | |
| RU2607498C2 (ru) | Жидкотекучие композиции для инъекций, включающие бупренорфин | |
| Sandker et al. | In situ forming acyl-capped PCLA–PEG–PCLA triblock copolymer based hydrogels | |
| US20140219923A1 (en) | Biodegradable compositions suitable for controlled release | |
| Zhang et al. | Sustained release of levobupivacaine from temperature-sensitive injectable hydrogel for long-term local anesthesia in postoperative pain management | |
| IL190486A (en) | Compounds of hydrophobic polymers undergoing glaciation and containing radical acid and their uses | |
| AU2011294295A1 (en) | Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles | |
| CA2926169C (fr) | Compositions a liberation continue a base d'acide hyaluronique, et leurs applications therapeutiques | |
| EP3068373B1 (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use | |
| US20090324741A1 (en) | Injectable polymer-lipid blend | |
| AU2012289968A1 (en) | Stable anti-inflammatory solutions for injection | |
| KR20190143555A (ko) | 카토제닌 유도체를 포함하는 고분자 미셀, 히알루론산 하이드로겔 및 이의 제조방법 및 그 용도 | |
| EP3285761B1 (en) | Parthenolide and its derivatives for use in the treatment of axonal damage | |
| KR20230161453A (ko) | 약제학적 조성물 | |
| US20250099598A1 (en) | Analgesic Therapeutics Based on Conjugation of Biocompatible Polymers to Ion Channel Modulators | |
| Zhong et al. | Anti-inflammatory effect of a novel piperazino-enaminone delivered by liposomes in a mouse model of hemophilic arthropathy | |
| KR102062690B1 (ko) | 이미다졸-폴리(유기포스파젠) 하이드로겔을 포함하는 척수 손상 예방 또는 치료용 조성물 | |
| Pastukh et al. | Injectable hyaluronic acid–metformin conjugate gel for sustained intra‐articular delivery and prevention of post‐traumatic osteoarthritis | |
| WO2025068983A1 (en) | Analgesic therapeutics based on conjugation of biocompatible polymers to ion channel modulators | |
| Shao et al. | A pH-responsive injectable hydrogel that modulates the inflammatory microenvironment for the treatment of osteoarthritis | |
| Johnston | Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues | |
| WO2024254258A2 (en) | Method of treating an articular condition or a condition of a bony canal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200529 |
|
| EEER | Examination request |
Effective date: 20200529 |